Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register

US Most-Favoured-Nation Drug Pricing: The Ripple Effect on Launches Worldwide

Mitul Agarwal
Written by Mitul Agarwal · B.Pharm, MBA
Founder & Head of Business Development · 25+ years in international pharmaceutical BD&L
Published 21 November 2026
US Most-Favoured-Nation Drug Pricing: The Ripple Effect on Launches Worldwide

By the PharmaTradz BD Team. Published November 2026.

In short: US "most-favoured-nation" pricing deals tie American prices for new branded medicines to the lowest prices in a basket of wealthy countries. That gives originators a reason to raise prices or delay launches in those reference countries, and to be careful about low-price markets that might be used as benchmarks. For buyers in Europe and emerging markets, expect slower launches of some new brands, more demand for named-patient imports, and a stronger case for generics and biosimilars.

Most pharma pricing news is local. This one is not. Decisions made in Washington about what Americans pay for new brands are now feeding directly into when, and at what price, the same brands reach the rest of the world.

What the MFN deals require

By 31 August 2026 the US administration said 26 manufacturers had signed most-favoured-nation pricing agreements, which it described as covering 89% of the branded drug market (White House). The main commitments are:

  • New launches at MFN prices. Companies agree to launch new innovative medicines in the US at prices no higher than those in comparable wealthy countries.
  • Medicaid access at MFN prices. State Medicaid programmes receive the lower prices.
  • Direct-to-consumer sales. The TrumpRx platform, launched in February 2026, listed 79 brand drugs from 16 manufacturers by late August, at 10% to 95% below list price (Peterson-KFF Health System Tracker).
  • Investment in return for tariff relief. Companies that pair MFN pricing with US manufacturing investment receive relief from the new pharmaceutical tariffs.

Much of the detail is confidential, and independent analysts have pointed out that key terms are missing from public information (KFF).

Which countries are the benchmark

The Peterson-KFF comparison uses 11 peer countries: Australia, Austria, Belgium, Canada, France, Germany, Japan, the Netherlands, Sweden, Switzerland and the United Kingdom. In its sample of 32 brand drugs, TrumpRx prices were below the peer average for 17 and above it for 15, so the US is not yet paying the lowest price across the board.

The ripple effect outside the US

If a company's US price for a new medicine is capped at what a reference country pays, every discount it gives in that country now costs it far more. The logical responses are:

  1. Higher prices in reference countries. The US administration itself reported that its December 2025 agreement with the UK raises net prices paid for new medicines there by 25%.
  2. Delayed or skipped launches. A company may wait to launch in a market until US pricing is set, or avoid markets where it would have to accept a low price. Analysts say it is still too early to measure this, but the incentive is clear.
  3. More confidential discounts. Rebates and managed-entry agreements hide the real net price, so list prices abroad may rise while net prices move less.

Emerging markets are not in the US reference basket, but many of them reference European prices in turn. A higher list price in Europe can therefore travel to the Middle East, Latin America and Asia through their own reference pricing rules.

What it means for buyers, distributors and manufacturers

  • Hospital buyers and importers should expect longer gaps between a new brand's US approval and its local launch for some products. Named-patient and special-import routes will carry more of the early demand.
  • Distributors with licences to import unregistered medicines on prescription will see more enquiries for newly approved brands not yet launched locally.
  • Generic and biosimilar manufacturers benefit: higher brand prices abroad make the savings from generics and biosimilars larger, which strengthens the case for faster substitution and tenders.
  • Regional pharma companies that in-license brands for their markets may find originators more cautious about price and more interested in partners who can manage confidential pricing and controlled launches.

Our view

We think the MFN deals will lower some US prices and raise some prices elsewhere, and the net effect for global patients is mixed. The clearest losers are smaller and lower-income markets that were already late in the launch queue; they risk waiting even longer for new medicines. The clearest winners are generics, biosimilars and the companies that supply them, because the price gap they close is getting wider.

For businesses in emerging markets, the practical response is not to wait for launches but to build the channels that serve patients in the gap: compliant named-patient import, reliable sourcing of medicines approved abroad, and early preparation for generic and biosimilar entry when exclusivity ends. Price policy in one country now shapes access in all of them, and planning should reflect that.

Related reading on PharmaTradz

The bottom line

US most-favoured-nation pricing is a domestic policy with global consequences. Expect higher brand prices and slower launches in some markets, and plan supply channels and generic strategies accordingly.

This article is general business information, not legal or pricing advice. Agreements and policies are changing; check the current position with the relevant authority or a qualified adviser.


Frequently Asked Questions(FAQs)

What is most-favoured-nation drug pricing?

A US policy, implemented mainly through company agreements, that ties US prices for new branded medicines to the lowest prices paid in a group of comparable wealthy countries.

How many companies have signed MFN agreements?

The US administration said 26 manufacturers had signed by 31 August 2026, covering what it described as 89% of the branded drug market.

Which countries are used as price benchmarks?

Analyses of TrumpRx prices use 11 peer countries: Australia, Austria, Belgium, Canada, France, Germany, Japan, the Netherlands, Sweden, Switzerland and the UK.

Will MFN pricing delay drug launches in other countries?

It gives originators a reason to raise prices or delay launches in reference markets. Analysts say it is too early to measure, but higher prices for new medicines have already been agreed in the UK.

How does MFN pricing affect emerging markets?

Many emerging markets reference European prices, so higher European list prices can spread. Launches may also come later, which increases demand for named-patient imports and strengthens the case for generics and biosimilars.

Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.

Category: Pharma Blogs

← Back to All Articles

 

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us